Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.59 |
| ▸ | MAOA | P21397 | 2/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 8/20 | 0.56 |
| ▸ | HTR2C | P28335 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048302 | 0.83 | HTR2A (0.55) | MAOBMAOAACHEHTR2AHTR2C | |
| SCHEMBL16686040 | 0.81 | NPC1 (0.63) | MAOBMAOAACHEMAPTNPC1 | |
| SCHEMBL4915737 | 0.78 | HTR2A (0.49) | HTR2AHTR2CKMT2AMAPTNPC1 | |
| SCHEMBL26630402 | 0.77 | NPC1 (0.55) | MAOBMAOAACHEMAPTNPC1 | |
| SCHEMBL13106085 | 0.77 | TRPM5 (0.64) | MAOBMAOAACHEKMT2AMEN1 | |
| SCHEMBL13106663 | 0.76 | CES1 (0.53) | HTR2AHTR2CKMT2AMEN1ALDH1A1 | |
| SCHEMBL29510910 | 0.76 | NPC1 (0.78) | MAOBMAOAACHEKMT2AMEN1 | |
| SCHEMBL31036105 | 0.76 | NOTUM (0.61) | MAOBMAOAACHEKMT2AMEN1 | |
| SCHEMBL13106151 | 0.76 | KMO (0.51) | MAOBMAOAACHEKMT2AMAPT | |
| SCHEMBL16406932 | 0.75 | NOTUM (0.54) | MAOBMAOAACHEMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | claimed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | claimed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1786422-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | Prosidion Limited (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006018662-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | PROSIDION LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | MAOB 1455/4885MAOA 2160/4885ACHE 2646/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | MAOB 1455/4885MAOA 2160/4885ACHE 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.